Key points from article :
A British company named LabGenius has secured a substantial investment of €8.9 million to further develop its innovative drug discovery technology. This tech cleverly combines artificial intelligence and robotics to speed up and improve the process of creating new medicines.
LabGenius specialises in developing protein-based therapeutics, a type of medicine that has shown great promise in treating a variety of diseases. Their secret weapon is an AI-powered "robot scientist" called EVA, which has the unique ability to analyse vast amounts of data generated in the lab. EVA learns from these experiments, creating models that can more accurately predict how changes in DNA will affect the function of proteins.
This is a big deal because traditional methods for discovering protein therapeutics have been slow and heavily reliant on human expertise. EVA's ability to process and learn from complex biological data at an unprecedented scale could revolutionise the field.
Currently, LabGenius is also developing new drugs for inflammatory bowel disease. With this new funding, they plan to expand their team and use their technology to create antibody-based drugs for conditions where there's a significant unmet medical need.
LabGenius is at the forefront of a growing trend towards laboratory automation in the biotech industry. This approach has the potential to significantly accelerate the development of new and more effective treatments for a wide range of diseases.
